Company Mabpharm Limited

Equities

2181

KYG5780F1046

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 01:39:00 03/05/2024 pm IST			5-day change	1st Jan Change
0.395 ^HKD	0.00%		-4.82%	-14.13%

26/03	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
10/01	Livzon Pharma Recognizes Credit, Asset Impairments	MT

Mabpharm Ltd is China-based company mainly engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The Company mainly conducts its businesses in China market.

Number of employees: 347

HKD in Million	2022	Weight	2023	Weight	Delta
Monoclonal Antibody Drugs 100.0 %	65	100.0 %	96	100.0 %	+48.11%

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	65	100.0 %	96	100.0 %	+48.11%

Managers	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	55	20/18/20
Yun Feng Li DFI	Director of Finance/CFO	47	20/18/20
Tao Jing BRD	Director/Board Member	51	03/18/03
Zhuge Wenhui SAM	Sales & Marketing	-	01/18/01
Ho Yin Tsang SEC	Corporate Secretary	38	31/19/31

Members of the board	Title	Age	Since
Shu Ge Jiao CHM	Chairman	58	20/18/20
Ho Ming Leung BRD	Director/Board Member	41	17/22/17
Wei Zhu Qian FOU	Founder	48	04/15/04
Hao Wang CEO	Chief Executive Officer	55	20/18/20
Yun Feng Li DFI	Director of Finance/CFO	47	20/18/20
Liang Zhong Guo BRD	Director/Board Member	58	10/18/10
Yan Yun Zhang BRD	Director/Board Member	68	10/18/10
Tao Jing BRD	Director/Board Member	51	03/18/03
Sheng Hou BRD	Director/Board Member	47	28/11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,124,080,000	941,260,140 ( 22.82 %)	0	22.82 %

Name	Equities	%	Valuation
Jian Jun Guo 54.00 %	2,227,000,000	54.00 %	141 M $
CDH Investment Advisory Pte. Ltd. 18.00 %	742,348,180	18.00 %	47 M $
Link Best Capital Ltd. 5.175 %	213,435,680	5.175 %	13 M $
Wei Zhu Qian 0.000000 %	0	0.000000 %	- $
Hao Wang 0.000000 %	0	0.000000 %	- $
Yun Feng Li 0.000000 %	0	0.000000 %	- $
Jing Li 0.000000 %	0	0.000000 %	- $
Tao Jing 0.000000 %	0	0.000000 %	- $
Sheng Hou 0.000000 %	0	0.000000 %	- $

Mabpharm Ltd.

18/F, Room A, Hong Xiang Centre 83 Queen's Road East

, Hong Kong

http://www.mabpharm.cn

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MABPHARM LIMITED	-14.13%	209M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B

Bio Therapeutic Drugs